GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangxi Fushine Pharmaceutical Co Ltd (SZSE:300497) » Definitions » Cash-to-Debt

Jiangxi Fushine Pharmaceutical Co (SZSE:300497) Cash-to-Debt : 0.42 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Jiangxi Fushine Pharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Jiangxi Fushine Pharmaceutical Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.42.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Jiangxi Fushine Pharmaceutical Co couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Jiangxi Fushine Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

SZSE:300497' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39   Med: 1.1   Max: 3.82
Current: 0.42

During the past 13 years, Jiangxi Fushine Pharmaceutical Co's highest Cash to Debt Ratio was 3.82. The lowest was 0.39. And the median was 1.10.

SZSE:300497's Cash-to-Debt is ranked worse than
86.59% of 1521 companies
in the Biotechnology industry
Industry Median: 6.39 vs SZSE:300497: 0.42

Jiangxi Fushine Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Jiangxi Fushine Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Jiangxi Fushine Pharmaceutical Co Cash-to-Debt Chart

Jiangxi Fushine Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 3.82 1.42 0.73 0.45

Jiangxi Fushine Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.47 0.48 0.45 0.42

Competitive Comparison of Jiangxi Fushine Pharmaceutical Co's Cash-to-Debt

For the Biotechnology subindustry, Jiangxi Fushine Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangxi Fushine Pharmaceutical Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangxi Fushine Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Jiangxi Fushine Pharmaceutical Co's Cash-to-Debt falls into.



Jiangxi Fushine Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Jiangxi Fushine Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Jiangxi Fushine Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangxi Fushine Pharmaceutical Co  (SZSE:300497) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Jiangxi Fushine Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Jiangxi Fushine Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangxi Fushine Pharmaceutical Co (SZSE:300497) Business Description

Traded in Other Exchanges
N/A
Address
No.2 YULI Industrial Zone, Changjiang district, Jiangxi Province, Jingdezhen, CHN, 333000
Jiangxi Fushine Pharmaceutical Co Ltd is engaged in research and development, manufactures and sells APIs and pharmaceutical intermediates. It offers penicillin, carbapenem, and other products.
Executives
Bao Jian Hua Directors, executives
Li Hui Yue Director
Peng Yun Secretary Dong
Dai Zhen Liang Executives
Yang Guang Executives
Chen Ying Hui Executives
Ke Dan Director
Xu Chun Xia Directors, executives
Yu Wen Jun Director
Cheng Rong Wu Directors, executives
Liu Ying Executives
Liu Zhi Min Executives
Tang De Ping Executives
Wang Ying Mei Director

Jiangxi Fushine Pharmaceutical Co (SZSE:300497) Headlines

No Headlines